Brelovitug
Chronic Hepatitis Delta Virus (HDV)
Phase 3AZURE-1 Enrollment Completed, AZURE-4 Screening Completed
Key Facts
Indication
Chronic Hepatitis Delta Virus (HDV)
Phase
Phase 3
Status
AZURE-1 Enrollment Completed, AZURE-4 Screening Completed
Company
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is dedicated to addressing severe unmet needs in rare liver diseases through its expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully commercialized LIVMARLI® and is advancing a robust clinical pipeline, including brelovitug for chronic hepatitis delta virus. With a patient-centric approach and a seasoned leadership team, Mirum aims to deliver life-changing medicines to underserved patient communities globally.
View full company profile